NASDAQ:PULM Pulmatrix (PULM) Stock Price, News & Analysis → The Worst is Yet to Come… (From Porter & Company) (Ad) Free PULM Stock Alerts $1.96 +0.09 (+4.81%) (As of 06/3/2024 ET) Add Compare Share Share Today's Range$1.90▼$1.9750-Day Range$1.63▼$2.1652-Week Range$1.55▼$2.88Volume6,838 shsAverage Volume12,653 shsMarket Capitalization$7.15 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Pulmatrix alerts: Email Address Pulmatrix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside410.2% Upside$10.00 Price TargetShort InterestHealthy0.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePulmatrix has received no research coverage in the past 90 days.Read more about Pulmatrix's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.01% of the float of Pulmatrix has been sold short.Short Interest Ratio / Days to CoverPulmatrix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmatrix has recently decreased by 86.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmatrix does not currently pay a dividend.Dividend GrowthPulmatrix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PULM. Previous Next 2.4 News and Social Media Coverage News SentimentPulmatrix has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pulmatrix this week, compared to 0 articles on an average week.Search Interest1 people have searched for PULM on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmatrix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.61% of the stock of Pulmatrix is held by insiders.Percentage Held by InstitutionsOnly 11.84% of the stock of Pulmatrix is held by institutions.Read more about Pulmatrix's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmatrix is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmatrix is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmatrix has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pulmatrix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About Pulmatrix Stock (NASDAQ:PULM)Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Read More PULM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PULM Stock News HeadlinesJune 4 at 3:14 AM | americanbankingnews.comPulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.comJune 3 at 2:34 AM | americanbankingnews.comHead to Head Analysis: Therapeutic Solutions International (OTCMKTS:TSOI) & Pulmatrix (NASDAQ:PULM)May 29, 2024 | prnewswire.comPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationMay 27, 2024 | americanbankingnews.comPulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.comMay 22, 2024 | msn.comTezepelumab Shows Potential for COPD, Negative Trial NotwithstandingMay 15, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 15, 2024 | prnewswire.comPulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 12, 2024 | finance.yahoo.comPulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)May 10, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comPULM Stock Earnings: Pulmatrix Reported Results for Q1 2024May 10, 2024 | prnewswire.comPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMarch 28, 2024 | investorplace.comPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdateFebruary 15, 2024 | morningstar.comCipla Ltd CIPLAJanuary 10, 2024 | bizjournals.comFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersJanuary 9, 2024 | bizjournals.comPulmatrix shuts down study, explores saleJanuary 8, 2024 | nasdaq.comPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The StudyJanuary 8, 2024 | marketwatch.comPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic AlternativesJanuary 8, 2024 | finance.yahoo.comPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic AlternativesJanuary 8, 2024 | msn.comStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata SteelJanuary 8, 2024 | msn.comStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In FocusNovember 12, 2023 | morningstar.comPulmatrix Inc PULMNovember 9, 2023 | baystreet.caPulmatrix Down on Q3 ResultsNovember 9, 2023 | msn.comPulmatrix GAAP EPS of -$1.03, revenue of $1.75MSee More Headlines Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/03/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees22Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+410.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net Margins-75.73% Pretax Margin-75.73% Return on Equity-44.05% Return on Assets-26.71% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual Sales$7.30 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book0.40Miscellaneous Outstanding Shares3,650,000Free Float3,520,000Market Cap$7.15 million OptionableNot Optionable Beta0.94 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Teofilo David Raad MBA (Age 54)President, CEO & Director Comp: $577.72kMr. Peter Ludlum CMA (Age 69)MBA, Interim CFO and Principal Accounting & Financial Officer Comp: $510.22kDr. Alexander M. Klibanov Ph.D. (Age 74)Founder Key CompetitorsNanoViricidesNYSE:NNVCTherapeuticsMDNASDAQ:TXMDAptorum GroupNASDAQ:APMAcasti PharmaNASDAQ:ACSTLisata TherapeuticsNASDAQ:LSTAView All Competitors PULM Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmatrix stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares. View PULM analyst ratings or view top-rated stocks. What is Pulmatrix's stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 410.2% from the stock's current price. View analysts price targets for PULM or view top-rated stocks among Wall Street analysts. How have PULM shares performed in 2024? Pulmatrix's stock was trading at $1.86 on January 1st, 2024. Since then, PULM shares have increased by 5.4% and is now trading at $1.96. View the best growth stocks for 2024 here. Are investors shorting Pulmatrix? Pulmatrix saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 400 shares, a drop of 86.2% from the April 30th total of 2,900 shares. Based on an average daily trading volume, of 15,100 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company's shares are sold short. View Pulmatrix's Short Interest. When is Pulmatrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our PULM earnings forecast. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Friday, May, 10th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $5.89 million for the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 44.05% and a negative net margin of 75.73%. When did Pulmatrix's stock split? Shares of Pulmatrix reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK). How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PULM) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersNvidia’s Quiet $1 Trillion PivotWeiss RatingsThe Only Energy Play You Should Be Looking AtWealthpin ProClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm PressPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.